All Posts Tagged With: "Rob Fannon"
Great Bargains in Ignored Biotech
There has been a lot of strong recommendations around biotech lately on Contrarian Profits.
Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.
There’s a good reason for this strength. A struggling economy won’t hurt biotech and medical as much as, say, an automaker, retailer, or restaurant chain… And biotech is one of the few industries showing solid sales growth.
Biotech Sector Could Jump 25% on Roche-Genentech Deal
Swiss drug company Roche (OTC:RHHBY) may not get its hands on San Francisco-based biotech outfit Genenetech (NYSE:DNA) as quickly as it had hoped.
Genetech has formed a special committee of independent directors to evaluate the $89-a-share acquisition offer from Roche, which already owns 56 percent of the US biotech firm.
If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…
While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry… and its investors.
With Genentech gone, the top of the biotech food chain is empty. Many investors will be searching for new spots to park their biotech cash. And sector valuations are on the rise. Both major biotech indexes – the Nasdaq Biotech Index and AMEX Biotech Index – are up more than 7% in just a few weeks.
Small-cap biotechs are cheap right now. So I’d be willing to bet the sector could jump 25% or more in the coming months. And big-cap names like Biogen (NASDAQ:BIIB), Genzyme (NASDAQ:GENZ), and Elan (NYSE:ELN) have jumped to the top of Big Pharma’s short list of buyout candidates.
If you’re thinking of dabbling in the biotech sector, Roche’s bid for Genentech just may be the buy signal you’re waiting for.
Source: The Buy Signal You’ve Waited For
How to Play the Uptrend in Biotech With ETFs
Another strong play from medical stock expert Rob Fannon.
Rob says that although Big Pharma stocks are cheap right now - bellwether Pfizer (PFE) is cheaper than it’s ever been - drugmakers are racing off the side of a cliff.
This is because when patents expire drugmakers loose billions of dollars to generic manufacturers.
But biotech drugs can’t be copied easily. And the sector is in an uptrend. Rob recommends using a biotech ETF to play this trend.
How to Profit from the Fall of Big Pharma
Big Pharma is in trouble. Generic competition, patent expirations and slowing sales are all eating into profits.
So how can you turn a profit in this turbulent sector? By investing in contract research organisations, or CROs, says biotech expert Rob Fannon. When the big pharmaceutical companies outsource research to CROs they get paid whether or not the new drugs ever make it to market.
There’s another way to profit too - contract sales organizations, or CSOs. They’re another way for Big Pharma to outsource, but instead of doing research they sell.
Latest News
- Base Metals Savaged1:58pm CDT
- Crude Still Slipping1:55pm CDT
- Dollar Flat Amid Dreadful Data1:52pm CDT
- Gold Edges Up, but Silver Hammered Again1:47pm CDT
- Brazilian Oil Takes Another Step Closer to Nationalization3:32pm CDT
- Resource Stock Roundup Friday, September 5th, 200812:01pm CDT
- Base Metals Treading Water11:53am CDT
- Crude Slips Further, $106 Seen as Support Level11:50am CDT
- Dollar Continues to Squash Euro11:47am CDT
- No Relief in Sight for Gold and Silver11:43am CDT
- Global Investing Roundups Friday, September 5th, 20089:39am CDT
- Weak Labor Market and Slowing Retail Sales Put U.S. Stocks in a Tailspin9:18am CDT
- Protest at Tata Plant Evidence of Indian Identity Crisis9:04am CDT
- Tap Into Korea’s Profit Potential with MSCI Korea Fund (EWY)8:02am CDT
- Follow PIMCO into Fannie and Freddie Bonds6:05am CDT
- Why You Should Buy Puts on the Weakest S&P 100 Players Now5:37am CDT
- Dollar Rally Means Mining Stocks On Sale5:11am CDT
- And Then There’s This… Thursday, September 4th, 200811:31am CDT
- Resource Stock Roundup Thursday, September 4th, 200811:26am CDT
